Research type:
|
Secondary Research (e.g. systematic review) |
Title (lead author) etc:
|
What is the clinical effectiveness and cost-effectiveness of using drugs in treating obese patients in primary care? A systematic review (Ara) 202 pages, Volume 16, number 5 |
DOI
|
10.3310/hta16050 |
View/print executive summary
View/print abstract
View full text in pdf format (17414 KB)
Go to our correspondence page to comment on this publication
|
Headline: |
Although orlistat, sibutramine and rimonabant are all effective at reducing weight and body mass index and, compared with placebo, are all cost-effective, both sibutramine and rimonabant have been withdrawn because of safety concerns relating to potential treatment-induced fatal adverse events. |
This report should be referenced as follows: |
Ara R, Blake L, Gray L, Hernandez M, Crowther M, et al. What is the clinical effectiveness and cost-effectiveness of using drugs in treating obese patients in primary care? A systematic review. Health Technol Assess
2012;16(5).
|
Project ref: |
07/85/02 |
Original project title: |
What is the clinical effectiveness and cost-effectiveness of using drugs in treating obese patients in primary care? A systematic review |
Chief Investigator: |
Ms Roberta Ara, Operational Research Analyst,
ScHARR, University of Sheffield
|
Start Date: |
January 2009 |
Date of publication in HTA journal series |
February 2012
|
Cost: |
£160,252 |
Project Protocol: |
Project protocol not available
|
Printed copies of this title despatched:
|
103 (Figures relate to the previous calendar month) |
URL of this page: |
http://www.hta.ac.uk/1761 |
News feeds